GENETON S.R.O.

Their core work

Geneton is a Slovak biotech SME specializing in computational genomics and bioinformatics, with particular strength in pangenome data analysis — the computational challenge of representing and querying multiple complete genomes simultaneously. They develop and apply graph-based algorithms and data structures for genome comparison and indexing. Their work also extends into structural biology, contributing to research on tau protein pathology relevant to Alzheimer's disease through techniques like NMR and cryo-EM.

What they specialise in

How they've shifted over time

Geneton entered H2020 in 2020 with a clear focus on computational pangenomics and graph-based genome algorithms (PANGAIA). They quickly diversified, joining InterTAU the same year to contribute bioinformatics capabilities to structural biology research on Alzheimer's-related tau proteins. By 2021, they reinforced their core pangenomics identity with ALPACA, suggesting the tau work was an opportunistic expansion rather than a strategic pivot.

Geneton is deepening its pangenomics expertise while selectively applying bioinformatics skills to biomedical problems like neurodegeneration, signaling readiness for interdisciplinary life science collaborations.

How they like to work

Geneton operates exclusively as a participant, never leading projects, which is typical for a specialized SME contributing targeted technical expertise to larger consortia. With 32 unique partners across just 3 projects, they work in large, internationally diverse MSCA networks rather than small focused teams. This breadth of connections suggests they are comfortable integrating into new groups and could serve as a flexible bioinformatics partner in future consortia.

Despite only three projects, Geneton has built a remarkably wide network of 32 partners across 18 countries, reflecting the large consortium nature of MSCA mobility schemes. Their reach spans most of Europe with no strong geographic concentration beyond their Slovak base.

What sets them apart

Geneton occupies a rare niche as a private-sector SME with deep expertise in pangenome algorithms — a field dominated by university groups. This makes them an attractive consortium partner when projects need industry participation with genuine computational genomics capability. Their dual competence in bioinformatics and structural biology data analysis gives consortium builders a versatile partner who can bridge computational and experimental biology teams.

Highlights from their portfolio

• PANGAIA
  Their largest funded project (EUR 251,160), addressing the frontier challenge of representing and querying pan-genome data through graph algorithms.
• InterTAU
  Represents a surprising diversification into Alzheimer's-related tau protein research, showing the company can apply computational skills beyond pure genomics.